Drugs / scp776
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05585606 | Oct 2022 → Sep 2025 | ischemic stroke | Silver Creek Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-10-23 | Silver Creek Pharmaceuticals | Results Silver Creek Pharmaceuticals Announces Positive Phase 2 Results for Scp776 in Acute Ischemic Stroke silvercreekpharma.com ↗
In the ARPEGGIO study, scp776 treatment resulted in clinically meaningful improvements in patient outcomes in a late intervention window stroke population that currently has no approved drug treatment – marking a potential breakthrough in stroke care. |
| 2025-10-17 | Silver Creek Pharmaceuticals | Regulatory Silver Creek Pharmaceuticals Receives FDA Fast Track Designation for Scp776 in Acute Ischemic Stroke silvercreekpharma.com ↗
the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to scp776, its investigational therapy for acute ischemic stroke, a condition with limited treatment options beyond reperfusion. |
| 2023-02-01 | Silver Creek Pharmaceuticals | Results World Stroke Conference 2023: Implementation of a Blood Glucose Management Plan for Scp776 silvercreekpharma.com ↗ |
| 2023-02-01 | Silver Creek Pharmaceuticals | Results International Stroke Conference 2023: ARPEGGIO Study Design silvercreekpharma.com ↗
Results demonstrated that scp776 is safe and well tolerated in healthy human subjects. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-23 | Silver Creek Pharmaceuticals | Silver Creek Pharmaceuticals Announces Positive Phase 2 Results for Scp776 in Acute Ischemic Stroke silvercreekpharma.com ↗ |
| 2025-10-17 | Silver Creek Pharmaceuticals | Silver Creek Pharmaceuticals Receives FDA Fast Track Designation for Scp776 in Acute Ischemic Stroke silvercreekpharma.com ↗ |
| 2023-02-10 | Silver Creek Pharmaceuticals | Silver Creek Presents ARPEGGIO, a Phase 2 Clinical Trial Evaluating Scp776 — a First-in-Class Cell Rescue Drug — for the Treatment of Acute Ischemic Stroke silvercreekpharma.com ↗ |
| 2023-02-01 | Silver Creek Pharmaceuticals | World Stroke Conference 2023: Implementation of a Blood Glucose Management Plan for Scp776 silvercreekpharma.com ↗ |
| 2023-02-01 | Silver Creek Pharmaceuticals | International Stroke Conference 2023: ARPEGGIO Study Design silvercreekpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | scp776 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05585606 ↗ |
| Route | Intravenous | “Intravenous (IV) slow injection(s) over 2 minutes” NCT05585606 ↗ |